Maze Therapeutics, Inc. (MAZE) Financials

MAZE Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 419.7 million 78.0 million
Dec. 31, 2025 397.1 million 42.2 million
Sept. 30, 2025 422.1 million 42.6 million
June 30, 2025 303.5 million 41.3 million

MAZE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -39.2 million 7.1 million
Dec. 31, 2025 -27.8 million 6.1 million
Sept. 30, 2025 -24.7 million 3.9 million
June 30, 2025 -30.4 million 3.2 million

MAZE Net Income

No data available :(

MAZE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 352.4 million 38.8 million 17.6 million
Dec. 31, 2025 341.9 million - 23.3 million
Sept. 30, 2025 383.9 million - 24.2 million
June 30, 2025 264.5 million - 25.0 million

MAZE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 53.9 million
Dec. 31, 2025 43.0 million
Sept. 30, 2025 45.8 million
June 30, 2025 43.9 million

MAZE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 93000 33.7 million 12.4 million -
Dec. 31, 2025 34000 27.6 million 10.5 million -
Sept. 30, 2025 68000 25.2 million 7.8 million -
June 30, 2025 393000 28.1 million 8.4 million -

MAZE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 20.0 million 444000
Dec. 31, 2025 - 499000
Sept. 30, 2025 - -
June 30, 2025 - 649000

MAZE

Price: $24.27

52 week price:
9.83
53.65

Earnings Per Share: -2.35 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 1.4 billion

Links: